Preserved in vivo response to interferon-alpha in multiple sclerosis patients with neutralising antibodies against interferon-beta (REPAIR study)

Multiple Sclerosis and Related Disorders

Volumn 2, Issue 2, 2013, Pages 141-146

  Magyari, Melinda ^a   Bach Søndergaard, Helle ^a   Sellebjerg, Finn ^a   Soelberg Sørensen, Per ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Beta interferon; Biomarkers; Disease modifying therapies; Immunology; Multiple Sclerosis; Neutralising antibodies

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MULTIFERON; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTHRALGIA; ARTICLE; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; GENE; GENE EXPRESSION; GENE INDUCTION; HUMAN; IFI27 GENE; IL10 GENE; IN VIVO STUDY; INJECTION SITE HYPERSENSITIVITY; MALE; MULTIPLE SCLEROSIS; MX1 GENE; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SKIN ALLERGY; TNFSF10 GENE; TREATMENT RESPONSE;

EID: 84872794019     PISSN: 22110348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.msard.2012.10.001     Document Type: Article

References (18)

1. L. Durelli, M.R. Bongioanni, and R. Cavallo Interferon alpha treatment of relapsing-remitting multiple sclerosis: long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune function. Multiple Sclerosis 1 Suppl 1 1995 S32 S37
2. L. Durelli, M.R. Bongioanni, and B. Ferrero Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment Neurology 47 1996 123 129
3. R. Farrell, R. Kapoor, and S. Leary Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta Multiple Sclerosis 14 2008 212 218
4. S.E. Grossberg, Y. Kawade, M. Kohase, and J.P. Klein The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit Journal of Interferon and Cytokine Research 21 2001 743 755
5. S.E. Grossberg, Y. Kawade, M. Kohase, H. Yokoyama, and N. Finter The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems Journal of Interferon and Cytokine Research 21 2001 729 742
6. D. Hesse, F. Sellebjerg, and P.S. Sørensen Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity Neurology 73 2009 372 377
7. P.E. Jensen, F. Sellebjerg, H.B. Søndergaard, and P.S. Sorensen Correlation between anti-interferon-beta binding and neutralizing antibodies in interferon-beta-treated multiple sclerosis patients European Journal of Neurology 2012
8. P. Kivisakk, G.V. Alm, S. Fredrikson, and H. Link Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis European Journal of Neurology 7 2000 27 34
9. J.F. Kurtzke Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) Neurology 33 1983 1444 1452
10. R. Lam, R. Farrell, and T. Aziz Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients Journal of Immunological Methods 336 2008 113 118
11. K.J Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method Methods 25 2001 402 408
12. K.M. Myhr, T. Riise, and F.E. Green Lilleas Interferon-alpha-2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian study group on Interferon-alpha in multiple sclerosis Neurology 52 1999 1049 1056
13. K.M. Myhr, C. Ross, H.I. Nyland, K. Bendtzen, and C.A. Vedeler Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive Neurology 55 2000 1569 1572
14. P. Perini, M. Calabrese, G. Biasi, and P. Gallo The clinical impact of interferon beta antibodies in relapsing-remitting MS Journal of Neurology 251 2004 305 309
15. P. Perini, A. Facchinetti, and P. Bulian Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo European Cytokine Network 12 2001 56 61
16. C. Ross, K.M. Clemmesen, and M. Svenson Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration Danish multiple sclerosis study group Annals of Neurology 48 2000 706 712
17. P.S. Sørensen, N. Koch-Henriksen, C. Ross, K.M. Clemmesen, and K. Bendtzen Appearance and disappearance of neutralizing antibodies during interferon-beta therapy Neurology 65 2005 33 39
18. P.S. Sørensen, C. Ross, and K.M. Clemmesen Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis Lancet 362 2003 1184 1191